Promising drugsExisting drugs have the potential to reduce hospitalizations and save lives, when used early to fight COVID-19.Based on our guiding principles, we’ve identified the following early treatments with the potential to significantly reduce hospitalization and fatality rates and worthy of further testing.Lessons learned include:The earlier the drug is given after a COVID infection, the more effective any drug treatment protocol will be, the faster the recovery, and the fewer the long-term side effects.There is no evidence that waiting for symptoms produces superior outcomes. The earlier the virus is treated the better. The protocols are safe enough that treating even before a PCR test result is returned is beneficial.Because these drugs are so safe, even treating young children is safe and reduces the risk of long-term disabilities. In short, the cost-benefit ratio even for young children argues for treating immediately after an infection is known. ...Other Promising DrugsThere are many other approved drugs and supplements with high effect sizes shown in multiple clinical trials. Ivermectin in particular has been shown to be extremely effective against COVID when given in sufficiently high doses as soon as possible after infection. Physicians using both ivermectin and fluvoxamine have reported extremely good results, especially when the drugs are given as early as possible after infection is confirm or first symptoms.We believe that both fluvoxamine and ivermectin are two of the most effective drugs that can be used against COVID. The evidence has been in plain sight since at least the middle of October 2020, yet the data has been ignored by the NIH and WHO. Had either of these agencies endorsed either either or both of these drugs at that time, it likely could have prevented the loss of hundreds of thousands of lives.Other drugs with large effect sizes are also effective for early treatment. The c19early.com website does an excellent job of highlighting other drugs and supplements that work the best.
The current epidemiology of rising COVID-19 hospitalizations serves as a strong impetus for an attempt at treatment in the days or weeks before a hospitalization occurs.1 Most patients who arrive to the hospital by emergency medical services with COVID-19 do not initially require forms of advanced medical care.2 Once hospitalized, approximately 25% require mechanical ventilation, advanced circulatory support, or renal replacement therapy. Hence, it is conceivable that some, if not a majority, of hospitalizations could be avoided with a treat-at-home first approach with appropriate telemedicine monitoring and access to oxygen and therapeutics. ... Zinc Lozenges and Zinc SulfateZinc is a known inhibitor of coronavirus replication. Clinical trials of zinc lozenges in the common cold have demonstrated modest reductions in the duration and or severity of symptoms.18 By extension, this readily available nontoxic therapy could be deployed at the first signs of COVID-19.19 Zinc lozenges can be administered 5 times a day for up to 5 days and extended if needed if symptoms persist. The amount of elemental zinc lozenges is <25% of that in a single 220-mg zinc sulfate daily tablet. This dose of zinc sulfate has been effectively used in combination with antimalarials in early treatment of high-risk outpatients with COVID-19.20 AntimalarialsHydroxychloroquine (HCQ) is an antimalarial/anti-inflammatory drug that impairs endosomal transfer of virions within human cells. HCQ is also a zinc ionophore that conveys zinc intracellularly to block the SARS-CoV-2 RNA-dependent RNA polymerase, which is the core enzyme of the virus replication.
InterpretationEarly administration of inhaled budesonide reduced the likelihood of needing urgent medical care and reduced time to recovery after early COVID-19.
We identified nine reports of early treatment outcomes in COVID-19 nursing home patients. Multi-drug therapy including hydroxychloroquine with one or more anti-infectives, corticosteroids, and antithrombotic anti-blood clotting agents can be extended to seniors in the nursing home setting without hospitalization. Data from nine studies found hydroxychloroquine-based multidrug regimens were associated with a statistically significant > 60% reduction in mortality.
The Bizarre Refusal to Apply Cost-Benefit Analysis to COVID Debates
Zinc Lozenges and Zinc SulfateZinc is a known inhibitor of coronavirus
Just look at the Irish - they subsisted on potatoes, onions, eggs, and the occasional chicken that they grew themselves for hundreds of years under the (racist? no it can't be racist because the english were also white) brutal english occupation, until the famine times.
stereotomy saysJust look at the Irish - they subsisted on potatoes, onions, eggs, and the occasional chicken that they grew themselves for hundreds of years under the (racist? no it can't be racist because the english were also white) brutal english occupation, until the famine times.The English did not consider the Irish to be the same race as them at all.Even when I worked in England for a summer in about 1993, I had to indicate my "race" on a visa form and the choices were:- white- black- Asian- IrishNot kidding. Wish I had kept a copy.
Local urgent care clinic posted this:
Analysis of 30 COVID-19 early treatments, and database of 231 other potential treatments. 67 countries have approved early treatments. Treatments do not replace vaccines and other measures. All practical, effective, and safe means should be used. Elimination is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all variants. Denying efficacy increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage.
Do you know why there isn't an EUA for fluvoxamine?The drug works. Amazingly well. Better than anything else against COVID when given early. So why isn't there an EUA? The answer will surprise you. Or maybe not.12 min ago The reason is simple. We tried. And after 6 weeks of waiting, we were told that to get an EUA for a repurposed drug, you have to partner with a drug company in the EUA application. Because no drug company will partner with us, even if we pay all the filing costs, there won’t be an EUA. Ever. So most doctors will never prescribe it for COVID, even thought it works better than anything else.
12/14/21COVID › VIEWSDr. McCullough Describes ‘Sinister Ways’ Doctors Worldwide Are Restricted From Treating COVID Patients“It seems to me, early on, there was an intentional, very comprehensive, suppression of early treatment in order to promote fear, suffering, isolation, hospitalization and death.”
December 16, 2021: After the Together trial results were published in the Lancet showing a 12X mortality benefit, the NIH subsequently claimed in their COVID Treatment Guidelines that fluvoxamine doesn’t work and refused to recommend it. I talked with three researchers who were familiar with the drug and they all said that the NIH decision was “disappointing.” I asked them if they would express this on camera and they all said “No.” Clearly, they don’t want to jeopardize future NIH grants. That tells you everything you need to know, doesn’t it?
NIH is still unsure whether fluvoxamine should be used to treat COVIDMore evidence of corruption at the NIH. I couldn't find a scientist that would be willing to defend the NIH's recommendation in a recorded interview. ...Can you see the difference between fluvoxamine and placebo? The NIH cannot.Have a look. This is a figure from the Lancet paper (Phase 3 fluvoxamine trial). The NIH basically looked at this and couldn’t figure out whether the drug works at all. To them, the placebo and fluvoxamine are identical. No signal there.
A former ICU nurse laid waste to the Covid narrative at her local county school board meeting this week, exposing how the medical authorities are responsible for coronavirus deaths by not promoting early treatment protocols.Speaking at a New Hanover County school board meeting in Wilmington, North Carolina, on Tuesday, registered nurse Morgan Wallace – who says she quit her job over vaccine mandates – slammed vaccines for failing to protect people from contracting Covid, and blamed government incompetence for leading to thousands of deaths.
WASHINGTON — The Biden administration quietly took nearly $7 billion from a fund meant to help hospitals and clinics affected by the pandemic and used it to buy Covid-19 vaccines and therapeutics, according to a document obtained by STAT.The move is similar to the Trump administration’s decision to divert $10 billion from the same fund to Operation Warp Speed, which STAT reported exclusively in March.
How a Sarasota Nurse Practitioner Saved Covid Lives Without VaccinesVanessa Hamalian and her new Latitude Clinic have treated 1,092 covid patients with ivermectin and the FLCCC protocols—none with vaccines. Of those, 1,091 have recovered.Matt Walsh